Chimeric Antigen Receptor T-cells - Gene Therapy of the Future for Malignant Diseases?
Chimeric antigen receptors are synthetic, genetically modified receptors of T-cells. The introduction of chimeric antigen receptors into autologous patient T-cells can redirect the lymphocytes to specific antigen targets on the surface of malignant cells. This has recently emerged as an intriguing therapy approach in both hematologic malignancies and later also in solid tumors. Various chimeric antigen receptor designs and manufacturing processes were developed and seem to have a strong impact on the activity of chimeric antigen receptor T-lymphocytes and thereby the therapy success. The individual variables are currently being tested in numerous clinical trials. In this review, I will briefly describe the principle, basic structure and construction of chimeric antigen receptor T-lymphocytes.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 Suppl 4 |
|---|---|
| Enthalten in: |
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 28 Suppl 4(2015) vom: 13., Seite 4S44-7 |
| Sprache: |
Tschechisch |
|---|
| Weiterer Titel: |
Chimérický antigenní receptor T lymfocytů - genová terapie budoucnosti u nádorových onemocnění? |
|---|
| Beteiligte Personen: |
Šmída, M [VerfasserIn] |
|---|
| Themen: |
English Abstract |
|---|
| Anmerkungen: |
Date Completed 11.01.2016 Date Revised 13.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM255383304 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM255383304 | ||
| 003 | DE-627 | ||
| 005 | 20231224174359.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||cze c | ||
| 028 | 5 | 2 | |a pubmed24n0851.xml |
| 035 | |a (DE-627)NLM255383304 | ||
| 035 | |a (NLM)26647888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a cze | ||
| 100 | 1 | |a Šmída, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chimeric Antigen Receptor T-cells - Gene Therapy of the Future for Malignant Diseases? |
| 246 | 3 | 3 | |a Chimérický antigenní receptor T lymfocytů - genová terapie budoucnosti u nádorových onemocnění? |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2016 | ||
| 500 | |a Date Revised 13.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chimeric antigen receptors are synthetic, genetically modified receptors of T-cells. The introduction of chimeric antigen receptors into autologous patient T-cells can redirect the lymphocytes to specific antigen targets on the surface of malignant cells. This has recently emerged as an intriguing therapy approach in both hematologic malignancies and later also in solid tumors. Various chimeric antigen receptor designs and manufacturing processes were developed and seem to have a strong impact on the activity of chimeric antigen receptor T-lymphocytes and thereby the therapy success. The individual variables are currently being tested in numerous clinical trials. In this review, I will briefly describe the principle, basic structure and construction of chimeric antigen receptor T-lymphocytes | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti |d 1998 |g 28 Suppl 4(2015) vom: 13., Seite 4S44-7 |w (DE-627)NLM09368763X |x 1802-5307 |7 nnns |
| 773 | 1 | 8 | |g volume:28 Suppl 4 |g year:2015 |g day:13 |g pages:4S44-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 Suppl 4 |j 2015 |b 13 |h 4S44-7 | ||